ADAP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADAP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Adaptimmune Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.180. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.84 for the trailing ten years ended in Dec. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
As of today (2024-04-28), Adaptimmune Therapeutics's current stock price is $1.075. Adaptimmune Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-0.84. Adaptimmune Therapeutics's Shiller PE Ratio of today is .
The historical data trend for Adaptimmune Therapeutics's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptimmune Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
E10 | Get a 7-Day Free Trial | - | - | - | - | -0.84 |
Adaptimmune Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
E10 | Get a 7-Day Free Trial | - | - | - | - | -0.84 |
For the Biotechnology subindustry, Adaptimmune Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Adaptimmune Therapeutics's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Adaptimmune Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.18 | / | 130.0000 | * | 130.0000 | |
= | -0.180 |
Current CPI (Dec. 2023) = 130.0000.
Adaptimmune Therapeutics Quarterly Data
per share eps | CPI | Adj_EPS | |
201306 | 0.000 | 98.000 | 0.000 |
201312 | 0.000 | 99.200 | 0.000 |
201406 | 1.489 | 99.800 | 1.940 |
201409 | -0.008 | 100.000 | -0.010 |
201412 | -0.004 | 99.900 | -0.005 |
201506 | -0.300 | 100.100 | -0.390 |
201509 | -0.018 | 100.200 | -0.023 |
201512 | -0.282 | 100.400 | -0.365 |
201603 | -0.240 | 100.400 | -0.311 |
201606 | -0.300 | 101.000 | -0.386 |
201609 | -0.240 | 101.500 | -0.307 |
201612 | -0.240 | 102.200 | -0.305 |
201703 | -0.300 | 102.700 | -0.380 |
201706 | -0.240 | 103.500 | -0.301 |
201709 | -0.009 | 104.300 | -0.011 |
201712 | -0.300 | 105.000 | -0.371 |
201803 | -0.240 | 105.100 | -0.297 |
201806 | -0.480 | 105.900 | -0.589 |
201809 | 0.060 | 106.600 | 0.073 |
201812 | -0.360 | 107.100 | -0.437 |
201903 | -0.240 | 107.000 | -0.292 |
201906 | -0.420 | 107.900 | -0.506 |
201909 | -0.360 | 108.400 | -0.432 |
201912 | -0.300 | 108.500 | -0.359 |
202003 | -0.240 | 108.600 | -0.287 |
202006 | -0.240 | 108.800 | -0.287 |
202009 | -0.240 | 109.200 | -0.286 |
202012 | -0.240 | 109.400 | -0.285 |
202103 | -0.240 | 109.700 | -0.284 |
202106 | -0.240 | 111.400 | -0.280 |
202109 | -0.300 | 112.400 | -0.347 |
202112 | -0.240 | 114.700 | -0.272 |
202203 | -0.300 | 116.500 | -0.335 |
202206 | -0.300 | 120.500 | -0.324 |
202209 | -0.240 | 122.300 | -0.255 |
202212 | -0.180 | 125.300 | -0.187 |
202303 | 0.006 | 126.800 | 0.006 |
202306 | -0.120 | 129.400 | -0.121 |
202309 | -0.180 | 130.100 | -0.180 |
202312 | -0.180 | 130.000 | -0.180 |
Add all the adjusted EPS together and divide 10 will get our e10.
Adaptimmune Therapeutics (NAS:ADAP) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Adaptimmune Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Elliot Norry | officer: Chief Medical Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Bertrand William C Jr | officer: Chief Operating Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
John Lunger | officer: Chief Patient Supply Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Adrian Rawcliffe | officer: Chief Financial Officer | 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146 |
Kristen Hege | director | 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070 |
Garry E Menzel | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Priti Hegde | director | TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142 |
Andrew R Allen | director | 2525 28TH STREET, SUITE 200, BOULDER CO 80301 |
Cintia Piccina | officer: Chief Commercial Officer | 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R |
Gavin Wood | officer: Chief Financial Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Joanna Elizabeth Brewer | officer: Chief Scientific Officer | 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Helena Katrina Tayton-martin | officer: Chief Operating Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
David M Mott | director | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Lawrence M Alleva | director | 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
James Noble | director, officer: Chief Executive Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
From GuruFocus
By Marketwired Marketwired • 09-05-2021
By Marketwired Marketwired • 10-21-2021
By GF Value • 06-16-2021
By sperokesalga sperokesalga • 03-29-2023
By GuruFocusNews GuruFocusNews • 05-26-2022
By PRNewswire PRNewswire • 05-20-2021
By Marketwired Marketwired • 05-11-2021
By Don Li2 Don Li2 • 11-11-2021
By PRNewswire PRNewswire • 03-23-2023
By Marketwired Marketwired • 05-19-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.